Executive Chairman & Director
Philip Astley-Sparke is Executive Chairman and co-founder of Replimune. Previously he was the President and CEO of BioVex Inc, which developed the first oncolytic vaccine to be approved in the West following the approval of Imlygic in 2015. Philip relocated the Company from the UK to the US in 2005 before the company was acquired by Amgen for up to $1bn ($675m paid to date) in 2011. Subsequent to BioVex/Amgen, Philip was President at uniQure where he established their US infrastructure including the world’s largest gene therapy manufacturing facility and now serves as the Company’s Chairman. Philip is also currently a Venture Partner at Forbion Capital and Chairman of Oxyrane. Philip received a BSc in Cellular and Molecular Pathology from Bristol University UK, qualified as a Chartered Accountant with Arthur Andersen and was a healthcare investment banker with Robert Fleming / Chase H&Q prior to joining BioVex.
CEO & Director
Robert Coffin is co-founder and CEO of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his research group at University College London in 1999. Rob was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC; Imlygic) and oversaw all research and clinical development including bringing T-VEC through to two pivotal phase 3 studies in melanoma and head & neck cancer. BioVex was acquired by Amgen in 2011 where Rob was VP Global Development until 2013. T-VEC was approved by the FDA for use in advanced melanoma in October 2015, the first oncolytic therapy or gene therapy to be approved in the US. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.
Chief Operating Officer
Colin Love most recently provided consultancy support to a range of companies from small gene therapy start-ups to large established biotech companies. He has over 30 years experience developing and launching biotechnology products and led development teams for Medeva, Serono and Amersham, prior to joining BioVex. Colin was SVP of Product Development at BioVex from 2000 until it was acquired by Amgen in 2011. Following the acquisition, he remained at Amgen as VP of R&D Operations working on T-VEC until it was approved in 2015.
Chief Business Officer
Pamela Esposito serves as Chief Business Officer of Replimune. Pamela has held a variety of strategy, commercial and business development positions in small biotech companies over the past 15 years, playing lead roles in transformative deals for each company. Previously, she was Chief Business Officer at Ra Pharmaceuticals. As a member of Ra’s senior management team, Pamela played a leadership role in strategy, helping Ra transform from a discovery platform to a clinical stage company and raising approximately $58 million in a Series B mezzanine funding round. Prior to Ra, she was VP of Business Development at Biovex and led the negotiation of the acquisition of the company by Amgen. Pamela earned a Ph.D. in pharmacology from Tufts University School of Medicine and a B.A. from Dartmouth College.
Anne Marie Woodland
Senior Vice President of Regulatory Affairs and Quality Assurance
Annie Woodland most recently had regulatory responsibility for all early stage and commercial products at uniQure Inc. Prior to joining uniQure, Annie was Executive Director and Global Regulatory Lead for T-VEC at Amgen/Biovex. She has extensive regulatory and quality expertise in the biopharmaceutical industry, specifically the areas of gene therapy and biologics and has held positions at CombinatoRx, Inc, Dyax Corp., Curis, Inc. (previously Reprogenesis), T-Cell Diagnostics and Baxter Dade.
Vice President of Clinical Development
Susan Doleman joined Replimune from Epizyme where she was Senior Director, Clinical Operations. From 2006-2015, Susan had increasing responsibility at BioVex/Amgen where she ultimately led clinical operations for the pivotal Phase 3 program with T-VEC until BLA filing. Previously Susan has held clinical operations roles at a number of biotechnology companies including Critical Therapeutics Inc, ToleRX Inc and Genzyme Corp.
Executive Medical Director
Tess Schmalbach has held multiple senior clinical positions at biotechnology and healthcare companies, including Chief Medical Officer at Dyax Inc, Vice President, Clinical Development at Coley Pharmaceuticals, and Director, Clinical Research at Vertex Pharmaceuticals. Previously she was a Fellow in Clinical Pharmacology at Harvard Medical School and received her medical training at the University of Medicine and Dentistry of New Jersey. She is currently an independent consultant, having previously provided consulting services to BioVex, and also provides services to Replimune on a consultancy basis.
Vice President of Research
Suzanne Thomas is VP of Research and is responsible for the construction, testing and preclinical production of Replimune’s developmental products. Suzanne held similar roles at BioVex and subsequently Amgen from 2001-2014 and was instrumental in the development of Imlygic (talimogene laherparepvec) among other programs. Suzanne was a post-doctoral fellow at University College London before joining BioVex and earned a PhD in Virology from the University of Warwick.